top of page
STARLIGHT ILLUSTRATED Latest Media Coverage..
NEWSMEDIA MAGAZINE *New York *LA*London*Paris*Frankfurt*Rome*Madrid*Tokyo*Vienna*Beijin*Zurich*Johannesburg*
WALL STREET STATION
P.O. BOX 859
NEW YORK, N.Y. 10268
RONALD S. LAUDER HONORED AT CONNOISSEUR’S DINNER Annual Gala Raised over $3.25 million for Alzheimer’s Treatments
New York, NY, April 29, 2016 – On Thursday, April 28, Ronald S. Lauder was honored by the Alzheimer’s Drug Discovery Foundation’s at its Tenth Annual Connoisseur’s Dinner at Sotheby’s in New York City. The event raised over
$3.25 million for Alzheimer’s research.
Leonard A. Lauder presented his brother, Ronald, with the Chairman’s Award for his leadership in supporting new treatments for Alzheimer’s disease. In a rousing acceptance speech, Ronald told the nearly 300 guests: “Leonard and I have been involved together in many causes over the years, but this cause, this effort means more to me than almost anything else.”The dinner was hosted by Nancy Corzine, a longtime member of the ADDF’s Board.
Guests including Donald E. Newhouse, Herbert Kasper, Jo Carole Lauder, Judy Glickman Lauder, William Lauder and Lori Tritsch, Tad Smith, Mary Freda, Jean Kennedy Smith, Lois Robbins, John Demsey, Ann and Andrew Tisch, Olivier Reza, Eleanora Kennedy, and Sheila Johnson Robbins enjoyed an exclusive preview of Sotheby’s Spring Impressionist, Modern and Contemporary Art Sale. The elegant evening also featured wine pairings selected by Sotheby’s and the dynamic “Fund a Scientist” auction, led by Jamie Niven. The auction raised funds for scientists working in epigenetics, an emerging area of research with enormous potential for Alzheimer’s and other diseases. All donations made to the ADDF support drug discovery research for Alzheimer’s disease.
About the Alzheimer’s Drug Discovery Foundation:
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded nearly $90 million to fund more than 500 Alzheimer’s drug discovery programs and clinical trials in 18 countries. To learn more, please visit: http://www.alzdiscovery.org/.
bottom of page